1. 1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome. (31st December 2020) Authors: Talarico, Christine L; Wu, Sterling; Upadhyay, Ojesh R; Clair, Marty St; Van Eygen, Veerle; Hudson, Krischan J; Griffith, Sandy; Harrington, Conn M; van Lunzen, Jan; Margolis, David; Spreen, William Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S540 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies. (31st December 2020) Authors: Teichner, Paula; Wu, Sterling; Zhang, Feifan; Dorey, David; D'Amico, Ronald; Griffith, Sandy; Sutton, Kenneth; McCoig, Cynthia C; Upadhyay, Ojesh R; Polli, Joseph; Margolis, David; Van Solingen-Ristea, Rodica; Vandermeulen, Kati; Spreen, William; Patel, Parul Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S544 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results. (31st December 2020) Authors: Chounta, Vasiliki; Bernal, Enrique; Lombaard, Johan; Katner, Harold P; Walmsley, Sharon; Dorey, David; Spreen, William; Griffith, Sandy; Margolis, David Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S548 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study. (31st December 2020) Authors: Mills, Anthony; Richmond, Gary J; Newman, Cheryl; Osiyemi, Olayemi; Cade, Jerry; Brinson, Cynthia; De Vente, Jerome; Andany, Nisha; Margolis, David; Sutton, Kenneth; Wilches, Viviana; Roberts, Jeremy; McCoig, Cynthia C; Vandermeulen, Kati; Spreen, William Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results. (31st December 2020) Authors: Smith, Graham; Henry, Keith; Podzamczer, Daniel; Masiá, Mar; Bettacchi, Christopher; Arasteh, Keikawus; Jaeger, Hans; Khuong-Josses, Marie-Aude; Sutton, Kenneth; Zhang, Feifan; McCoig, Cynthia C; Vandermeulen, Kati; Van Solingen-Ristea, Rodica; Spreen, William; Margolis, David Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S379 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 833. Efficacy and Safety of Long-Acting Cabotegravir + Rilpivirine in Participants with HIV/HCV Co-infection: ATLAS-2M 48-Week Results. (4th December 2021) Authors: D'Amico, Ronald; Benn, Paul; Thiagarajah, Shanker; Ford, Susan L; Birmingham, Eileen; Upadhyay, Ojesh R; Garside, Louise; Van Solingen-Ristea, Rodica; Vandermeulen, Kati; Spreen, William Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S508 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 877. North American Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes. (4th December 2021) Authors: Taiwo, Babafemi O; Tan, Darrell; Patel, Parul; Teichner, Paula; Polli, Joseph; Garside, Louise; D'Amico, Ronald; Talarico, Christine L; Van Solingen-Ristea, Rodica; Baugh, Bryan; Spreen, William; Aboud, Michael; Bosse, Matthew Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S530 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials. (4th December 2021) Authors: Patel, Parul; Ford, Susan L; Baker, Mark; Meyer, Claudia; Garside, Louise; D'Amico, Ronald; Van Solingen-Ristea, Rodica; Crauwels, Herta; Polli, Joseph; Seal, Ciara; Thiagarajah, Shanker; Birmingham, Eileen; Spreen, William; Baugh, Bryan; Bosse, Matthew; Vannappagari, Vani Journal: Open forum infectious diseases Issue: Volume 8(2021)Supplement 1 Page Start: S534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Effect of a High‐Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir. Issue 4 (19th September 2018) Authors: Patel, Parul; Ford, Susan L.; Lou, Yu; Bakshi, Kalpana; Tenorio, Allan R.; Zhang, Zhiping; Pan, Rennan; Spreen, William Journal: Clinical pharmacology in drug development Issue: Volume 8:Issue 4(2019) Page Start: 443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects. Issue 4 (May 2019) Authors: Ford, Susan L; Lou, Yu; Lewis, Nicole; Kostapanos, Michalis; D'Amico, Ronald; Spreen, William; Patel, Parul Journal: Antiviral therapy Issue: Volume 24:Issue 4(2019) Page Start: 301 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗